Drugs & Therapy Perspectives

, Volume 12, Issue 11, pp 10–13 | Cite as

Outlook for transplant recipients with CMV infection improved with appropriately targeted treatment

New Drugs and Disease Management
  • 10 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hebart H, Kanz L, Jahn G, et al. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation: current guidelines and future prospects. Drugs 1998 Jan; 55(1): 59–72PubMedCrossRefGoogle Scholar
  2. 2.
    Meyers JD, Flourney N, Thomas E. Risk factors for cytomegalovirus infection after human bone marrow transplantation. J Infect Dis 1986; 153: 478–88PubMedCrossRefGoogle Scholar
  3. 3.
    Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term aciclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation: European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–53PubMedCrossRefGoogle Scholar
  4. 4.
    Bass EB, Powe NR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12: 273–82PubMedGoogle Scholar
  5. 5.
    Boeckh M, Gooley T, Reusser P, et al. Failure of high-dose acyclovir for prevention of CMV disease after autologous marrow transplant. J Infect Dis 1995; 172: 939–43PubMedCrossRefGoogle Scholar
  6. 6.
    Patel R, Wiesner RH, Paya CV. Prophylaxis and treatment of cytomegalovirus infection after solid organ transplantation. Clin Immunother 1996 Jan; 5(1): 13–29CrossRefGoogle Scholar
  7. 7.
    Stratta RJ, Wood RP, Langnas RM, et al. Donor selection for orthotopic liver transplantation: lack of an effect of gender or cytomegalovirus (CMV) status. Transplant Proc 1990; 22: 410–3PubMedGoogle Scholar
  8. 8.
    Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279–89PubMedCrossRefGoogle Scholar
  9. 9.
    Balfour Jr HH, Chace BA, Stapleton JT, et al. A randomised, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381–7PubMedCrossRefGoogle Scholar
  10. 10.
    Winston DJ, Wirin D, Shaked A, et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69–74PubMedCrossRefGoogle Scholar
  11. 11.
    Kelly JL, Albert RK, Wood DE, et al. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995; 59: 1144–7PubMedGoogle Scholar
  12. 12.
    Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients — a meta-analysis. Clin Transplant 1994; 8: 10–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 1998

Personalised recommendations